Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Pharma
BioMarin lays off staffers at recently-acquired Amicus
Shortly after locking down its $4.8 billion deal for rare disease peer Amicus, BioMarin is pruning the acquired company's ranks.
Fraiser Kansteiner
May 12, 2026 5:12pm
Chiesi grows rare disease ambitions with $1.9B KalVista buyout
Apr 29, 2026 10:01am
Neurocrine pays $2.9B for Soleno, its largest M&A deal ever
Apr 6, 2026 10:30am
M&A surge triggers high expectations for 2026
Apr 6, 2026 5:00am
Veeva pays $100M for Ostro and its pharma-focused AI chat tool
Mar 11, 2026 11:55am
Esperion pays $75M for Corstasis and FDA-approved nasal spray
Mar 3, 2026 8:40am
